Subscribe

Angela Lamb, MD: Breaking the Itch-Scratch Cycle in Prurigo Nodularis

Angela Lamb, MD, an associate professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York, discusses recent advancements in understanding and treating prurigo nodularis and chronic itch disorders. She highlights the role of interleukin (IL)-31 in driving the itch-scratch cycle. She explains that nemolizumab (Nemluvio) targets the IL-31 receptor, which is expressed on dorsal root ganglion cells, mast cells, basophils, and keratinocytes, helping to disrupt key itch signaling pathways.

Topics Covered:

  • Understanding pruritus and its impact on patients with prurigo nodularis
  • Mechanism of action and immunological insights
  • Efficacy and safety of nemolizumab 

Explore Related Resources:
Patient Presentation and Clinical Trial Data for Prurigo Nodularis
Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management

MORE EXPERT PERSPECTIVES IN PRURIGO NODULARIS:

Walter J. Liszewski, MD: Mechanisms of Action in Prurigo Nodularis

Walter J. Liszewski, MD, an associate professor of dermatology at Northwestern University, discusses mechanisms of action to consider for treatment of patients with prurigo nodularis.

PLAY
David Cotter, MD, PhD: Patient Presentation and Clinical Trial Data for Prurigo Nodularis

Dr. Cotter, a board-certified dermatologist at Las Vegas Dermatology, presents a real-world case of Prurigo Nodularis, highlighting both the severity of disease presentation and the

PLAY
Jenny Murase, MD: Assessing Symptoms and Presentation of Patients with Prurigo Nodularis

Dr. Murase reviews the clinical presentation of Prurigo Nodularis, a chronic inflammatory skin condition characterized by intensely pruritic nodules and significant disease burden. She outlines

PLAY
James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

Drs. Del Rosso and Cotter discuss how advances in the molecular understanding of Prurigo Nodularis have led to the development of targeted therapies that address

PLAY
Diego Ruiz Dasilva, MD, FAAD: Providing Treatment for Challenging Cases of Chronic Pruritus

Dr. Dasilva presents findings from a real-world case series evaluating treatment options for patients with treatment-resistant chronic pruritus, highlighting the marked efficacy of Nemolizumab. His

PLAY